1.
Rev. esp. enferm. dig
; 114(4): 195-197, abril 2022.
Artigo
em Espanhol
| IBECS
| ID: ibc-205595
2.
Rev Esp Enferm Dig
; 114(4): 195-197, 2022 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35315679
RESUMO
The therapeutic management of hepatocellular carcinoma (HCC) has achieved great advances in the past few years. Before the publication of the SHARP clinical trial, which showed the effectiveness of sorafenib in patients with advanced HCC, no effective systemic therapy was available and only transarterial chemoembolization (TACE) had shown an impact on survival in clinical trials.